IGF-1 LR3 Mechanism of Action — Research Reference

IGF-1 LR3 Mechanism of Action

IGF-1 LR3 is a modified IGF-1 analog used to examine how sequence changes alter binding-protein interactions and receptor-signalling duration. The Long R3 IGF-1 catalog reference lists the material specifications and batch-documentation pathway associated with this research compound.

Molecular modification

LR3 includes a 13-amino-acid N-terminal extension and an arginine-for-glutamate substitution at position 3. Together, these changes produce an 83-amino-acid analog with lower affinity for several IGF-binding proteins than native IGF-1 in experimental models.

IGF-1 receptor activation

The IGF-1 receptor is a receptor tyrosine kinase. Ligand binding promotes receptor autophosphorylation and recruitment of intracellular signalling proteins. LR3 research measures this activation under defined assay conditions and compares the result with native IGF-1 or other structural variants.

PI3K-AKT-mTOR signalling

One major downstream branch involves insulin-receptor-substrate proteins, phosphoinositide 3-kinase, AKT, and mTOR-associated signalling. Researchers measure phosphorylation states, protein-synthesis markers, and related cellular responses to characterize pathway magnitude and persistence.

RAS-MAPK signalling

A second commonly measured branch proceeds through adaptor proteins, RAS, RAF, MEK, and ERK. This cascade is studied through proliferation, differentiation, and transcriptional endpoints in controlled cellular systems.

Why IGFBP affinity matters

IGFBPs influence the distribution and availability of IGF-family ligands. Reduced binding by LR3 changes how much unbound analog is available to interact with IGF-1R during an experiment. This makes exposure timing, assay design, and an appropriate native-IGF-1 control important when interpreting results.

Distinguishing LR3 from IGF-1 DES

LR3 uses extension and substitution to create an extended signalling profile. DES(1-3) uses N-terminal truncation and is investigated in short-window or localized-signalling models. They should be identified and analyzed as separate molecular variants.

Research scope

The mechanism described here concerns receptor binding, molecular interactions, and cellular-pathway measurements in laboratory systems. Its scope is limited to laboratory receptor, binding-protein, pathway, and cellular-endpoint research.

References

• Bryant KJ et al. Design and characterisation of Long R3 insulin-like growth factor-I muteins. Growth Factors. 1996.
• Xi G et al. Effects of IGFBP-3 on IGF-I and Long R3 IGF-I signalling in myogenic cells. Journal of Cellular Physiology. 2004.

Running the numbers for a protocol? Use the research calculators to convert mg, mL, and syringe units.